STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
526
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $1.4M priced
What the filings say about CPRT
Insiders, 180 days
-$3.6M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-08-19
Planned sales (Form 144), 90 days
$551.3K
1 notice
Copart insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, COPART INC insiders sold a net $3.6M of stock across 54 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Apr 15, 2026.
The trade is 27.8% of the 99,641 shares held after it.
1 other insider sold within 30 days.
526 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Liaw Jeffrey sold about $845.9K of CPRT on Jul 28, 2026; 1 other insider sold within 30 days and 526 funds added in the latest 13F quarter.
4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jan 6, 2025.
The trade is 29.1% of the 275,352 shares held after it.
1 other insider sold within 30 days.
526 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Englander Daniel J sold about $2.2M of CPRT on Jul 13, 2026; 1 other insider sold within 30 days and 526 funds added in the latest 13F quarter.
Nobody has filed for crossing 5%. That is a fact, not missing data.
CPRT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Morefield Diane M
Filed 2026-10-15
$551.3K
JEFF LIAW
Filed 2026-07-28
$826.5K
URSULA CAPITAL PARTNERS LP
Filed 2026-07-13
$2.2M
CPRT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
YCG Enhanced Fund
$32.6M position · as of 2026-05-31
6.4%
Akre Focus ETF
$203.8M position · as of 2026-07-31
3.9%
NYLIM WMC Enduring Capital Fund
$12.1M position · as of 2026-07-31
3.5%
Jensen Quality Mid Cap Fund
$3.3M position · as of 2026-05-31
3.5%
LONE PEAK VALUE FUND
$4.4M position · as of 2026-06-30
2.6%
Madison Mid Cap Fund
$43.0M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Liaw
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2026
$2.1M
-$5.2M
$2.2M
-21%
+16%
2025
$2.1M
-$1.9M
$744.2K
+23%
+8%
2021
$490.6K
$39.3M
$7.8M
+58%
+25%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.6M sold by insiders over 180 days, 526 funds added last quarter, $551.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.7B
four quarters, 2025-08-01 to 2026-07-31
Revenue, TTM CPRT
FY Jul 2026
$4.7B
FY Jul 2025
$4.6B
FY Jul 2024
$4.2B
FY Jul 2023
$3.9B
FY Jul 2022
$3.5B
Jul 2026
$1.2B
Apr 2026
$1.2B
Jan 2026
$1.1B
Oct 2025
$1.2B
Jul 2025
$1.1B
Apr 2025
$1.2B
Jan 2025
$1.2B
Oct 2024
$1.1B
At each fiscal year end
Single quarter
Net margin, TTM
+31.8%
net income over revenue, 2025-08-01 to 2026-07-31
Net margin, TTM CPRT
FY Jul 2026
+31.8%
FY Jul 2025
+33.4%
FY Jul 2024
+32.2%
FY Jul 2023
+32.0%
FY Jul 2022
+31.1%
Jul 2026
+28.4%
Apr 2026
+32.5%
Jan 2026
+31.3%
Oct 2025
+35.0%
Jul 2025
+35.2%
Apr 2025
+33.6%
Jan 2025
+33.3%
Oct 2024
+31.6%
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.3B
operating cash flow minus capex, 2025-08-01 to 2026-07-31
Free cash flow, TTM CPRT
FY Jul 2026
$1.3B
FY Jul 2025
$1.2B
FY Jul 2024
$961.6M
FY Jul 2023
$847.6M
FY Jul 2022
$838.7M
Jul 2026
$278.7M
Apr 2026
$503.3M
Jan 2026
$57.9M
Oct 2025
$427.2M
Jul 2025
$350.8M
Apr 2025
$630.4M
Jan 2025
$4.0M
Oct 2024
$245.5M
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2024-07-31 (24 months older than the period end); equity 2026-07-31
Debt to equity CPRT
FY Jul 2026
0.00x
FY Jul 2025
0.00x
FY Jul 2024
0.00x
FY Jul 2023
0.00x
FY Jul 2022
0.00x
Jul 2026
0.00x
Apr 2026
0.00x
Jan 2026
0.00x
Oct 2025
0.00x
Jul 2025
0.00x
Apr 2025
0.00x
Jan 2025
0.00x
Oct 2024
0.00x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt CPRT
FY Jul 2026
n/a
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
123.95x
FY Jul 2022
589.52x
Jul 2026
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+16.2%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on equity CPRT
FY Jul 2026
+16.2%
FY Jul 2025
+18.6%
FY Jul 2024
+20.2%
FY Jul 2023
+23.3%
FY Jul 2022
+26.7%
Jul 2026
+16.2%
Apr 2026
+17.7%
Jan 2026
+17.2%
Oct 2025
+18.2%
Jul 2025
+18.6%
Apr 2025
+18.5%
Jan 2025
+19.3%
Oct 2024
+19.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.8%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on assets CPRT
FY Jul 2026
+14.8%
FY Jul 2025
+16.8%
FY Jul 2024
+18.0%
FY Jul 2023
+20.5%
FY Jul 2022
+22.1%
Jul 2026
+14.8%
Apr 2026
+16.1%
Jan 2026
+15.7%
Oct 2025
+16.4%
Jul 2025
+16.8%
Apr 2025
+16.7%
Jan 2025
+17.3%
Oct 2024
+17.2%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+18.1%
operating income after a 19.3% effective tax rate, over long-term debt only, 2024-07-31 (24 months older than the period end) plus average of 2025-07-31 and 2026-07-31 minus cash
Return on invested capital CPRT
FY Jul 2026
+18.1%
FY Jul 2025
+21.1%
FY Jul 2024
+25.1%
FY Jul 2023
+33.5%
FY Jul 2022
+39.0%
Jul 2026
+18.1%
Apr 2026
+19.7%
Jan 2026
+18.9%
Oct 2025
+20.3%
Jul 2025
+21.1%
Apr 2025
+21.5%
Jan 2025
+22.9%
Oct 2024
+23.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+17.6%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
Return on capital employed CPRT
FY Jul 2026
+17.6%
FY Jul 2025
+19.7%
FY Jul 2024
+22.4%
FY Jul 2023
+26.8%
FY Jul 2022
+30.5%
Jul 2026
+17.6%
Apr 2026
+18.9%
Jan 2026
+18.2%
Oct 2025
+19.2%
Jul 2025
+19.7%
Apr 2025
+20.0%
Jan 2025
+20.8%
Oct 2024
+21.3%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
18.81x
close 2026-10-26 over four quarters of diluted EPS, 2025-08-01 to 2026-07-31
P/E, trailing CPRT
FY Jul 2026
18.79x
FY Jul 2025
28.33x
FY Jul 2024
37.65x
FY Jul 2023
34.80x
FY Jul 2022
28.09x
Jul 2026
18.79x
Apr 2026
20.57x
Jan 2026
25.36x
Oct 2025
26.23x
Jul 2025
28.33x
Apr 2025
40.15x
Jan 2025
38.88x
Oct 2024
36.25x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$24.9B
market value at close 2026-10-26 on 2026-09-25 shares, plus long-term debt only, 2024-07-31 (24 months older than the period end), minus cash 2023-04-30
Enterprise value CPRT
FY Jul 2026
$24.8B
FY Jul 2025
$41.7B
FY Jul 2024
$48.2B
FY Jul 2023
$19.0B
FY Jul 2022
$6.2B
Jul 2026
$24.8B
Apr 2026
$29.8B
Jan 2026
$37.2B
Oct 2025
$39.5B
Jul 2025
$41.7B
Apr 2025
$56.8B
Jan 2025
$53.7B
Oct 2024
$47.5B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield CPRT
FY Jul 2026
+4.7%
FY Jul 2025
+2.8%
FY Jul 2024
+1.9%
FY Jul 2023
+4.0%
FY Jul 2022
+11.0%
Jul 2026
+4.7%
Apr 2026
+4.2%
Jan 2026
+3.7%
Oct 2025
+3.4%
Jul 2025
+2.8%
Apr 2025
+2.0%
Jan 2025
+1.7%
Oct 2024
+2.0%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -3%, PEG needs growth
PEG, trailing CPRT
FY Jul 2026
n/a
FY Jul 2025
1.88x
FY Jul 2024
3.98x
FY Jul 2023
3.05x
FY Jul 2022
1.60x
Jul 2026
n/a
Apr 2026
3.47x
Jan 2026
3.44x
Oct 2025
1.69x
Jul 2025
1.88x
Apr 2025
5.70x
Jan 2025
5.40x
Oct 2024
8.22x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
CPRT ranks highest on financial health (99th percentile) and institutional and government (91st), and lowest on insider conviction (16th), among Wholesale & Retail peers.
Profitability
73
Inputs
Return on equity+16.2% · 70 pct, sector of 206
Return on assets+14.8% · 90 pct, sector of 257
Return on invested capital+18.1% · 56 pct, sector of 109
Return on capital employed+17.6% · 76 pct, sector of 220
Financial health
100
Inputs
Debt to equity0.00x · 100 pct, sector of 222
Cash flow to debtno debt to cover
Growth
37
Inputs
Revenue growth, YoY+0.4% · 37 pct, sector of 311
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
16
Inputs
Net Form 4 buying (codes P and S), 180d-$3.6M · 32 pct, sector of 187
Insider buyers, 180d0 · 0 pct, sector of 189
Institutional and government
91
Inputs
Funds adding, latest quarter526 · 91 pct, sector of 234
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
58
Inputs
Short interest, % of float+3.4% · 55 pct, sector of 320
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5y0.00 per $1B · 100 pct, sector of 242
New text in Risk Factors, latest 10-K+21.6% · 18 pct, sector of 226
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CPRT filings, in plain words
Are Copart insiders buying or selling CPRT?
In the 180 days to 2026-10-28, Copart insiders were net sellers, a net $3.6M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded CPRT?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Valerie Hoyle dated 2025-08-19.
Are there planned insider sales of CPRT?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $551.3K of stock; the latest, by Morefield Diane M, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-28, Copart insiders were net sellers of CPRT, a net $3.6M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in CPRT, none in the last year; the latest on record is a sale by Valerie Hoyle dated 2025-08-19. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $551.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.